CoChat

Guideline on the management of acute chest syndrome in sickle cell disease

Howard, Jo, Hart, Nicholas, Roberts‐Harewood, Marilyn, Cummins, Michelle, Awogbade, Moji, Davis, Bernard · 2015 · British Journal of Haematology
Cited by 186

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Sickle cell disease (SCD) affects 12 000–15 000 individuals in the UK. Whilst homozygous SCD (sickle cell anaemia — HbSS) is the most common and severe genotype, and is where most of the evidence exists, this guidance should be used for all genotypes of SCD. Acute chest syndrome (ACS) is defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on chest X-ray (Charache et al, 1979; Ballas et al, 2010). This definition encompasses cases both where an infective organism is isolated and where no infective cause is identified. It is unique to SCD but in some cases ACS may appear to be similar to bacterial pneumonia in a patient without SCD. ACS may have a severe clinical course and can progress rapidly from mild hypoxia to respiratory failure and death. The presence of hypoxia is not included in the definition, but in clinical practice, hypoxia is a useful predictor of severity and outcome (Vichinsky et al, 1997, 2000). Historically, ACS is one of the most common causes of death in patients with SCD (Platt et al, 1994; Lucas et al, 2008), although mortality is improving with improved medical management (Fitzhugh et al, 2010). ACS can also be associated with significant morbidity, including long-term parenchymal lung damage, pulmonary vascular abnormality and neurological sequelae. Patients may present to hospital acutely unwell with ACS or ACS may develop during a hospital admission following a painful crisis or post-operatively. This guideline will be useful for clinicians working in both high and low prevalence areas and may serve as the foundation for clinical governance measures that can be introduced in individual units with the aim of improving care for patients with SCD. It can be used to inform local pathways and protocols, and we recommend that all acute healthcare organizations should have a protocol for management of this condition (Sickle Cell Society, 2008). In specialist centres such pathways and protocols will be developed locally, but smaller centres should consider linking with a nearby specialist centre and using a shared protocol. Units in acute healthcare organizations in low prevalence areas who may only rarely be confronted with ACS should have clear guidance on: (i) which specialist centre to seek advice from, (ii) criteria for transfer to the specialist centre and (iii) criteria for transfer to a critical care intensive care unit (ICU) (level 3) or high dependency unit (HDU) (level 2). The guideline group was selected by the British Committee for Standards in Haematology (BCSH) to be representative of UK-based medical experts. MEDLINE and EMBASE were searched systematically for publications from 1966 until April 2013 using a variety of key words. The writing group produced the draft guideline, which was subsequently considered by the members of the General Haematology Task Force of the BCSH. The guideline was then reviewed by a sounding board of approximately 50 UK haematologists and members of the BCSH and British Society of Haematology Committee, patient representatives and other interested parties. Comments were incorporated where appropriate. The 'GRADE' system was used to quote levels and grades of evidence, details of which can be found in Appendix I. Criteria used to quote levels and grades of evidence are as outlined in the Procedure for Guidelines Commissioned by the BCSH (Appendix I). Acute chest syndrome refers to a spectrum of disease from a mild pneumonic illness to acute respiratory distress syndrome and multi-organ failure. The initial insult, which may be pulmonary infection, fat embolism and/or pulmonary infarction, causes a fall in alveolar oxygenation tension, which causes HbS polymerization. This, in turn, leads to decreased pulmonary blood flow that exacerbates vaso-occlusion, producing more severe hypoxia such that a vicious cycle of hypoxia, HbS polymerization, vaso-occlusion and altered pulmonary blood flow ensues. There is evidence that VCAM1, which is up-regulated by hypoxia and fat embolism, has a role in the development of ACS as an inducer of red cell adhesion It contributes to increased adherence of red cells to the respiratory endothelium and increased vaso-occlusion within the pulmonary circulation, leading to increased hypoxia (Stuart & Setty, 1999). Acute chest syndrome may occur secondary to infection, and infectious organisms were identified in 38% of cases who underwent detailed investigations including blood culture, nasopharyngeal sampling for viral culture, sputum culture and serum samples for antibody response and bronchoscopy (Vichinsky et al, 2000). The identification of a specific infectious organism is less likely with standard investigations alone. An infective aetiology is more common in children than in adults and shows seasonal variation in children, being three times more common in winter (Vichinsky et al, 1997). Viral infection is the commonest cause of ACS in children under

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.13348

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

  • Sickle cell disease

    Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501

See all 186

Metadata

Authors
Howard, J., Hart, N., Roberts‐Harewood, M., Cummins, M., Awogbade, M., & Davis, B.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2015-03-30
Volume
169
Issue
4
Pages
492-505
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2122876469
Cited by
186
References
14
FWCI
7.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.